MetaCap

Neogen Corporation (NEOG)

NASDAQ: NEOGHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD

10.55-0.30 (-2.76%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NEOG stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.26
52-week range
5.60 – 14.26
Day range
10.42 – 10.94
Volume / Avg
3.04M / 3.53M
Beta
—

52-week range

$5.60$14.26

NEOG stock today

Neogen (NEOG) closed at $10.55 on Nov 20, down 2.76% (-$0.30), versus the S&P 500's 3.70% decline. Shares are 26.0% below their 52-week high of $14.26, set on Sep 23, 2026 and 88.4% above the 52-week low of $5.60, in the middle of the past year's range. NEOG is up 50.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 84.4%.

Neogen has posted a net loss over the last twelve months (EPS of -$0.26), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Neogen

Company profile

Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns.

Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
CEO
Mr. Mikhael Nassif
Headquarters
Lansing, MI
Employees
2,636
IPO year
1989
Website
neogen.com

Financial highlights

Full financials

In fiscal 2026, Neogen generated $870.4 million in revenue, down 2.7% from fiscal 2025, its first annual decline since 2025. Neogen reported a net loss of $7.9 million, compared with a loss of $1.09 billion a year earlier. Gross margin was 46.9% (down from 47.1%) and operating margin -2.5%.

Neogen annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024FY 2023FY 2022
Revenue$870.40M$894.70M$924.20M$822.45M$527.16M
Growth-2.72%-3.19%+12.37%+56.01%+12.53%
Net income$-7.90M$-1.09B$-9.40M$-22.87M$48.31M
EPS (diluted)$-0.04$-5.03$-0.04$-0.12$0.45

Analyst forecast

Forecast

Consensus (4 analysts)

buy

Avg. price target

$14.00+32.70%

  • Strong buy 2
  • Buy 1
  • Hold 1
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Aug/2026)
Oct 6, 2026
EPS actual vs est.
$-0.05 vs $0.04
Surprise
-225.00%

NEOG news

All NEOG news

Neogen peers

Health Care sector
NEOG peer companies
CompanyPrice% ChgMarket capCompare
CLDXCelldex Therapeutics Inc.27.42-1.93%$2.15Bvs NEOG
NTLAIntellia Therapeutics Inc.10.00+5.04%$1.40Bvs NEOG
QUITAchieve Life Sciences Inc.5.56-5.28%$573.25Mvs NEOG
QDELQuidelOrtho Corporation8.32-6.73%$570.86Mvs NEOG
MYGNMyriad Genetics Inc.5.46-1.44%$523.74Mvs NEOG
TKNOAlpha Teknova Inc.7.63-2.30%$479.95Mvs NEOG
NNNNAnbio Biotechnology Class A3.32-9.04%$145.72Mvs NEOG
ICCCImmuCell Corporation10.92-2.41%$99.28Mvs NEOG

Indexes, lists and sector

Neogen stock FAQ

What is Neogen's stock price today?

NEOG last traded at $10.55 as of Nov 20, 4:00 PM EST, down 2.76% on the day. Prices are delayed at least 15 minutes.

Does Neogen pay a dividend?

No. Neogen does not currently pay a regular cash dividend.

Who is Neogen's CEO?

Mr. Mikhael Nassif is the chief executive officer of Neogen Corporation, which has about 2,636 employees.

Has NEOG ever split its stock?

Yes. The most recent NEOG stock split was a 2-for-1 split on Jun 7, 2021, one of 6 splits on record.

What is the NEOG 52-week high?

The 52-week high for NEOG is $14.26 and the 52-week low is $5.60. The stock is currently 26.0% below its high.

Compare NEOG